Tunable Genetic Switch for Transgene Expression Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene expression systems suffer from leakiness, where transgenes are not fully turned off, leading to background expression, which complicates research and therapeutic applications by causing unintended effects and toxicity, especially in tumor-specific targeting and gene therapy.
Innovation Solution
A tightly controlled inducible gene expression system using a synthetic RNAi agent that targets a non-coding region of the transgene, coupled with repressor proteins and inducible promoters, such as the Lac-Tet-RNAi system, to minimize background expression and allow precise spatial and temporal control of gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional gene expression systems (tetR, lacI, Gal4/UAS) are used to regulate transgene expression, then transcriptional control is achieved, but background expression (leakiness) cannot be completely eliminated
Solution Approach 1:
The system divides gene expression control into two independent stages: transcriptional control (via TetR/lacI repressors) and post-transcriptional control (via RNAi). This segmentation allows each mechanism to operate independently, with the RNAi component specifically targeting and degrading any leaky transgene mRNA, thereby eliminating background expression while preserving transcriptional regulation capability.
Solution Approach 2:
The invention introduces an intermediary mechanism (RNAi pathway) between transcription and protein production. The RNAi molecules act as mediators that specifically target and degrade transgene mRNA, preventing translation of leaky expression products. This intermediary layer provides an additional control point that completely eliminates background expression without affecting the primary transcriptional regulation system.
2Object-generated harmful factors
If RNAi is used to knock down transgene expression, then background expression is reduced, but off-target effects can affect genes not related to the gene of interest
Solution Approach 1:
The system applies local quality by designing RNAi molecules with specific sequence complementarity to the transgene mRNA. The RNAi agents are engineered to match only the target transgene sequence and not endogenous genes, ensuring that gene silencing occurs locally at the desired target while avoiding off-target effects in other genes. This specificity is achieved through careful selection of RNAi sequences that are unique to the transgene.
Solution Approach 2:
The invention uses synthetic RNAi molecules as copies or representations of the target gene sequence. These artificial RNAi molecules are designed to be complementary to the transgene but do not naturally occur in the cell, thereby silencing the transgene without affecting endogenous genes. The RNAi copies are introduced exogenously and provide sequence-specific silencing through their complementary binding to the target mRNA.
3Reliability
If cre recombinase is used to activate or inactivate gene expression, then permanent genetic modification is achieved, but regulation is restricted and tamoxifen can be toxic at required dosage levels
Solution Approach 1:
The invention replaces the mechanical/chemical recombination system (cre recombinase requiring tamoxifen) with a biochemical regulation system based on RNAi and transcriptional repressors. Instead of using permanent DNA recombination, the system uses reversible biochemical mechanisms (RNA binding, transcriptional repression) to control gene expression. This substitution eliminates the need for toxic tamoxifen while providing comparable or superior regulation capability through RNA-based mechanisms.
Solution Approach 2:
The system changes the regulatory parameter from permanent DNA recombination (cre) to reversible RNA-based control (RNAi and transcriptional repressors). This parameter change allows for tunable, reversible gene expression control without the toxicity associated with cre activation. The RNAi mechanism provides a softer, more controllable form of gene silencing that can be adjusted by varying RNAi molecule concentration and sequence specificity, eliminating the all-or-nothing recombination effect and associated tamoxifen toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves >99% repression of transgene expression in the off state and allows tunable, reversible control, reducing background expression to less than 1%, enabling safe and effective therapeutic applications and precise targeting.
Implementation Method 1
A commonly used method to activate or inactivate gene expression in mice involves the use of site-specific cre recombinase (cre). cre, which was derived from bacteriophage P1, mediates the deletion of a DNA sequence flanked by a pair of cre recognition sequences, called IoxP sites
Implementation Method 2
Several techniques exist to regulate gene expression; however, each carries its own caveat in function. It was discovered that both the tetR and lacI Escherichia coli repressor systems function in mammalian cell tissue culture and in mice
Implementation Method 3
The first repressor molecule is inhibited by a small molecule; and wherein the presence of the small molecule relieves repression of the first repressor promoter sequence thereby expression of the heterologous gene
Data Source
AI summary
The present invention relates generally the field of genetics, in particular methods, compositions and systems for controlling the inducible expression of transgenes, while eliminating background expression of transgene expression. The present invention relates to methods of use of the compositions and systems as disclosed herein for controlling the inducible expression of transgenes while eliminating background expression of transgene expression, such as use in, for example, the in generation of transgenic animals, use in therapeutic application and use in assays. In some embodiments, the present invention relates to a system of controlled expression of RNAi molecules which target binding sites in the untranslated regions of transgene, thereby the expression of the transgene is modulated and leakiness is reduced. The compositions and methods of the present invention can be used to for therapy, prophylaxis, research and diagnostics in diseases and disorders which afflict mammalian species, generation of transgenic animals, in the study of biological processes as well as for enhance performance of agricultural crops.